SECAUCUS, N.J. and SAN DIEGO, Dec. 1, 2021 /PRNewswire/ -- Physicians in the United States can now order the liquid biopsy-based Target Selector™ NGS Lung Panel test directly from Quest Diagnostics ...
Quest Diagnostics recently unveiled a suite of advanced diagnostics and support services designed to broaden access to lab tests for transplants. Quest hopes to improve testing compliance among ...
SECAUCUS, N.J., Feb. 24, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today introduced a new COVID-19 testing service that aids ...
Quest Diagnostics will soon begin offering a new blood-based in-vitro diagnostic test for Alzheimer’s. The disease affects nearly 7 million Americans. The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma ...
In just one week, Secaucus-based Quest Diagnostics announced two new product offerings: one for at-home consumer use and another for physicians. The consumer product, Genetic Insights, helps people ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced an agreement with Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information ...
Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. Developed by Fujirebio, the Lumipulse G test measures ...
Quest Diagnostics will work on a blood test for cancer risk it says may help identify people who could benefit from more frequent screenings using technology developed at the MD Anderson Cancer Center ...
Quest’s two AD-Detect blood-based tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer’s disease pathology in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback